Skip to content
Regenx Bio Logo


January 26, 2023

REGENXBIO has announced that their Phase I/II clinical trial of RGX-202, a gene therapy candidate for Duchenne muscular dystrophy, is now active and recruiting patients. Initial trial sites are located in the U.S., with additional sites in Canada and Europe expected to follow.

RGX-202 is designed to deliver a transgene for a novel microdystrophin protein that includes the functional elements of the C-Terminal (CT) domain found in naturally occurring dystrophin. RGX-202 uses REGENXBIO’s proprietary NAV® AAV8 vector.

AFFINITY DUCHENNE is a multicenter, open-label dose evaluation and dose expansion clinical trial to evaluate the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in patients with Duchenne.

Click the button below to learn more about this clinical trial:

Additionally, REGENXBIO is recruiting patients in the AFFINITY BEYOND trial, an observational screening study. The primary objective is to evaluate the prevalence of AAV8 antibodies in patients with Duchenne up to 12 years of age. Information collected in this study may be used to identify potential participants for the AFFINITY DUCHENNE trial and potential future trials of RGX-202.

Read the full press release here:

Related Articles